WEE1 and pancreatic neoplasm: In pancreatic cancer, preclinical models suggest a combinational approach of a WEE1 inhibitor with radio- and chemotherapy, and a phase I/II trial treated 34 patients with locally advanced PDAC with the WEE1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation therapy.